Development of clinical trials to extend healthy lifespan

Jamie N. Justice, Laura Niedernhofer, Paul D. Robbins, Vanita R. Aroda, Mark A. Espeland, Stephen B. Kritchevsky, George A. Kuchel, Nir Barzilai

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Significant progress in defining the biology of aging, particularly in animal models, supports the geroscience hypothesis, which posits that by therapeutically targeting biological aging, the onset of multiple age-related diseases can be delayed 'en suite'. Geroscience investigators are preparing to test this hypothesis in humans for the first time. In this review, we describe development of large-scale clinical trials designed to determine whether multiple age-related health conditions can be simultaneously alleviated with interventions targeting the underlying biology of aging. We describe the rationale and collaborative, consensus building approach used to design the first aging outcome trial called Targeting Aging with Metformin. Through this case study, we outline features that could be more broadly extended to other geroscience-guided clinical trials, including a process for selecting biochemical and molecular markers of biologic age and we provide a perspective on the potential impact of clinical trials targeting aging.

Original languageEnglish (US)
Pages (from-to)80-83
Number of pages4
JournalCardiovascular Endocrinology and Metabolism
Volume7
Issue number4
DOIs
StatePublished - Dec 1 2018

Fingerprint

Clinical Trials
Metformin
Age of Onset
Animal Models
Biomarkers
Research Personnel
Health

Keywords

  • aging
  • biomarkers
  • clinical trials
  • geroscience
  • healthspan
  • multimorbidity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Justice, J. N., Niedernhofer, L., Robbins, P. D., Aroda, V. R., Espeland, M. A., Kritchevsky, S. B., ... Barzilai, N. (2018). Development of clinical trials to extend healthy lifespan. Cardiovascular Endocrinology and Metabolism, 7(4), 80-83. https://doi.org/10.1097/XCE.0000000000000159

Development of clinical trials to extend healthy lifespan. / Justice, Jamie N.; Niedernhofer, Laura; Robbins, Paul D.; Aroda, Vanita R.; Espeland, Mark A.; Kritchevsky, Stephen B.; Kuchel, George A.; Barzilai, Nir.

In: Cardiovascular Endocrinology and Metabolism, Vol. 7, No. 4, 01.12.2018, p. 80-83.

Research output: Contribution to journalReview article

Justice, JN, Niedernhofer, L, Robbins, PD, Aroda, VR, Espeland, MA, Kritchevsky, SB, Kuchel, GA & Barzilai, N 2018, 'Development of clinical trials to extend healthy lifespan', Cardiovascular Endocrinology and Metabolism, vol. 7, no. 4, pp. 80-83. https://doi.org/10.1097/XCE.0000000000000159
Justice JN, Niedernhofer L, Robbins PD, Aroda VR, Espeland MA, Kritchevsky SB et al. Development of clinical trials to extend healthy lifespan. Cardiovascular Endocrinology and Metabolism. 2018 Dec 1;7(4):80-83. https://doi.org/10.1097/XCE.0000000000000159
Justice, Jamie N. ; Niedernhofer, Laura ; Robbins, Paul D. ; Aroda, Vanita R. ; Espeland, Mark A. ; Kritchevsky, Stephen B. ; Kuchel, George A. ; Barzilai, Nir. / Development of clinical trials to extend healthy lifespan. In: Cardiovascular Endocrinology and Metabolism. 2018 ; Vol. 7, No. 4. pp. 80-83.
@article{217426754bea4f679aef47d0f5cbddad,
title = "Development of clinical trials to extend healthy lifespan",
abstract = "Significant progress in defining the biology of aging, particularly in animal models, supports the geroscience hypothesis, which posits that by therapeutically targeting biological aging, the onset of multiple age-related diseases can be delayed 'en suite'. Geroscience investigators are preparing to test this hypothesis in humans for the first time. In this review, we describe development of large-scale clinical trials designed to determine whether multiple age-related health conditions can be simultaneously alleviated with interventions targeting the underlying biology of aging. We describe the rationale and collaborative, consensus building approach used to design the first aging outcome trial called Targeting Aging with Metformin. Through this case study, we outline features that could be more broadly extended to other geroscience-guided clinical trials, including a process for selecting biochemical and molecular markers of biologic age and we provide a perspective on the potential impact of clinical trials targeting aging.",
keywords = "aging, biomarkers, clinical trials, geroscience, healthspan, multimorbidity",
author = "Justice, {Jamie N.} and Laura Niedernhofer and Robbins, {Paul D.} and Aroda, {Vanita R.} and Espeland, {Mark A.} and Kritchevsky, {Stephen B.} and Kuchel, {George A.} and Nir Barzilai",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/XCE.0000000000000159",
language = "English (US)",
volume = "7",
pages = "80--83",
journal = "Cardiovascular Endocrinology and Metabolism",
issn = "2574-0954",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

TY - JOUR

T1 - Development of clinical trials to extend healthy lifespan

AU - Justice, Jamie N.

AU - Niedernhofer, Laura

AU - Robbins, Paul D.

AU - Aroda, Vanita R.

AU - Espeland, Mark A.

AU - Kritchevsky, Stephen B.

AU - Kuchel, George A.

AU - Barzilai, Nir

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Significant progress in defining the biology of aging, particularly in animal models, supports the geroscience hypothesis, which posits that by therapeutically targeting biological aging, the onset of multiple age-related diseases can be delayed 'en suite'. Geroscience investigators are preparing to test this hypothesis in humans for the first time. In this review, we describe development of large-scale clinical trials designed to determine whether multiple age-related health conditions can be simultaneously alleviated with interventions targeting the underlying biology of aging. We describe the rationale and collaborative, consensus building approach used to design the first aging outcome trial called Targeting Aging with Metformin. Through this case study, we outline features that could be more broadly extended to other geroscience-guided clinical trials, including a process for selecting biochemical and molecular markers of biologic age and we provide a perspective on the potential impact of clinical trials targeting aging.

AB - Significant progress in defining the biology of aging, particularly in animal models, supports the geroscience hypothesis, which posits that by therapeutically targeting biological aging, the onset of multiple age-related diseases can be delayed 'en suite'. Geroscience investigators are preparing to test this hypothesis in humans for the first time. In this review, we describe development of large-scale clinical trials designed to determine whether multiple age-related health conditions can be simultaneously alleviated with interventions targeting the underlying biology of aging. We describe the rationale and collaborative, consensus building approach used to design the first aging outcome trial called Targeting Aging with Metformin. Through this case study, we outline features that could be more broadly extended to other geroscience-guided clinical trials, including a process for selecting biochemical and molecular markers of biologic age and we provide a perspective on the potential impact of clinical trials targeting aging.

KW - aging

KW - biomarkers

KW - clinical trials

KW - geroscience

KW - healthspan

KW - multimorbidity

UR - http://www.scopus.com/inward/record.url?scp=85057628221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057628221&partnerID=8YFLogxK

U2 - 10.1097/XCE.0000000000000159

DO - 10.1097/XCE.0000000000000159

M3 - Review article

AN - SCOPUS:85057628221

VL - 7

SP - 80

EP - 83

JO - Cardiovascular Endocrinology and Metabolism

JF - Cardiovascular Endocrinology and Metabolism

SN - 2574-0954

IS - 4

ER -